RU2016149485A - Твердые формы ромидепсина и их применение - Google Patents
Твердые формы ромидепсина и их применение Download PDFInfo
- Publication number
- RU2016149485A RU2016149485A RU2016149485A RU2016149485A RU2016149485A RU 2016149485 A RU2016149485 A RU 2016149485A RU 2016149485 A RU2016149485 A RU 2016149485A RU 2016149485 A RU2016149485 A RU 2016149485A RU 2016149485 A RU2016149485 A RU 2016149485A
- Authority
- RU
- Russia
- Prior art keywords
- cellulose
- romidepsin
- amorphous
- amorphous romidepsin
- derivative
- Prior art date
Links
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 title claims 12
- 229960003452 romidepsin Drugs 0.000 title claims 12
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 title claims 12
- 108010091666 romidepsin Proteins 0.000 title claims 12
- 239000007787 solid Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims 6
- 229920002678 cellulose Polymers 0.000 claims 4
- 239000001913 cellulose Substances 0.000 claims 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 229920000642 polymer Polymers 0.000 claims 3
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 claims 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 2
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 claims 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 201000005962 mycosis fungoides Diseases 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 2
- 150000005846 sugar alcohols Chemical class 0.000 claims 2
- 238000002411 thermogravimetry Methods 0.000 claims 2
- -1 vinyl lactam Chemical class 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 239000004698 Polyethylene Substances 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 235000001465 calcium Nutrition 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 229940105329 carboxymethylcellulose Drugs 0.000 claims 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 230000009477 glass transition Effects 0.000 claims 1
- 229920000591 gum Polymers 0.000 claims 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 229960003943 hypromellose Drugs 0.000 claims 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- VORWPIMQKSQGDA-UHFFFAOYSA-N propan-2-ol 2,2,2-trifluoroethanol Chemical compound FC(CO)(F)F.C(C)(C)O VORWPIMQKSQGDA-UHFFFAOYSA-N 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
- 238000001757 thermogravimetry curve Methods 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Claims (11)
1. Аморфный ромидепсин.
2. Аморфный ромидепсин по п.1, характеризующийся порошковой рентгеновской дифрактограммой (XRPD), по существу такой как показано на Фиг.7(а).
3. Аморфный ромидепсин по п.2, где аморфный ромидепсин получают из смеси вода/дихлорметан.
4. Аморфный ромидепсин по п.2, где аморфный ромидепсин получают из смеси изопропанол-трифторэтанол/метанол.
5. Аморфный ромидепсин по любому из пп.1-4, где аморфный ромидепсин имеет температуру стеклования около 91oC.
6. Аморфный ромидепсин по любому из пп.1-4, где термограмма термогравиметрического анализа (TГA) демонстрирует потерю массы 3,5%.
7. Композиция, содержащая аморфный ромидепсин по п.1 и эксципиент, где эксципиент выбирают из группы, состоящей из производного целлюлозы, камеди, декстрана, виниллактама, циклодекстрина, желатина, фталата гипромеллозы, сахарного спирта, многоатомного спирта, полимера полиэтиленгликоля (ПЭГ), полиэтиленоксида, производного полиэтилена, поливинилового спирта, производного пропиленгликоля, лаурилсульфата натрия (SLS), твина, сополимера метакриловой кислоты, и аминокислоты.
8. Композиция по п.7, где эксципиент представляет собой производное целлюлозы.
9. Композиция по п.8, где производное целлюлозы представляет собой полимер гидроксипропилметилцеллюлозы (ГПМЦ), гидроксипропилцеллюлозу, этилцеллюлозу, гидроксиэтилцеллюлозу, карбоксиметилцеллюлозу натрия, кальцийкарбоксиметилцеллюлозу, или натриевую соль карбоксиметилцеллюлозы.
10. Композиция по п.9, где производное целлюлозы представляет собой полимер ГПМЦ.
11. Применение аморфного ромидепсина по любому из пп.1-6 в способе лечения кожной Т-клеточной лимфомы (CTCL) или периферической Т-клеточной лимфомы (PPCL).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36352210P | 2010-07-12 | 2010-07-12 | |
US61/363,522 | 2010-07-12 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013105700A Division RU2607634C2 (ru) | 2010-07-12 | 2011-07-12 | Твердые формы ромидепсина и их применение |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2016149485A true RU2016149485A (ru) | 2018-10-31 |
Family
ID=44514993
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013105700A RU2607634C2 (ru) | 2010-07-12 | 2011-07-12 | Твердые формы ромидепсина и их применение |
RU2016149485A RU2016149485A (ru) | 2010-07-12 | 2011-07-12 | Твердые формы ромидепсина и их применение |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013105700A RU2607634C2 (ru) | 2010-07-12 | 2011-07-12 | Твердые формы ромидепсина и их применение |
Country Status (16)
Country | Link |
---|---|
US (5) | US20120190817A2 (ru) |
EP (1) | EP2593123B1 (ru) |
JP (3) | JP6049614B2 (ru) |
KR (1) | KR20130092557A (ru) |
CN (1) | CN103108648A (ru) |
AU (1) | AU2011279303B2 (ru) |
BR (1) | BR112013000673A2 (ru) |
CA (1) | CA2804795A1 (ru) |
ES (1) | ES2755909T3 (ru) |
MX (1) | MX342913B (ru) |
MY (1) | MY185130A (ru) |
NZ (2) | NZ706052A (ru) |
RU (2) | RU2607634C2 (ru) |
SG (2) | SG187032A1 (ru) |
UA (1) | UA114074C2 (ru) |
WO (1) | WO2012009336A1 (ru) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0720734A2 (pt) * | 2006-12-29 | 2014-01-07 | Gloucester Pharmaceuticals Inc | Preparação da romidepsina |
DE102011090178A1 (de) * | 2011-12-30 | 2013-07-04 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation |
AU2013201937B8 (en) | 2012-01-12 | 2015-08-20 | Celgene Corporation | Romidepsin formulations and uses thereof |
AU2013202506B2 (en) | 2012-09-07 | 2015-06-18 | Celgene Corporation | Resistance biomarkers for hdac inhibitors |
CN103877010B (zh) * | 2012-12-21 | 2018-06-01 | 正大天晴药业集团股份有限公司 | 一种罗米地辛溶液的制备方法 |
WO2014102731A1 (en) * | 2012-12-31 | 2014-07-03 | Leiutis Pharmaceuticals Pvt. Ltd | Novel pharmaceutical compositions of romidepsin |
ITMI20131856A1 (it) * | 2013-11-08 | 2015-05-09 | Gnosis Spa | Processo per la preparazione di differenti forme cristalline del s-acetil glutatione e loro utilizzi in formulazioni farmaceutiche e nutraceutiche |
CN103861084A (zh) * | 2014-02-12 | 2014-06-18 | 新乡医学院 | Romidepsin在治疗帕金森病中的应用 |
CN104262456B (zh) * | 2014-09-11 | 2018-01-09 | 浙江海正药业股份有限公司 | 一种罗米地辛的新晶型及其制备方法和用途 |
WO2016210292A1 (en) | 2015-06-25 | 2016-12-29 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
AU2017235461B2 (en) | 2016-03-15 | 2023-02-23 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
CN105801667B (zh) * | 2016-03-22 | 2019-04-09 | 浙江海正药业股份有限公司 | 一种制备无定型罗米地辛的方法 |
BR112019010077A2 (pt) * | 2016-11-22 | 2019-10-01 | Alkalidx Inc | terapias para o tratamento de condições hipocalêmicas e de ineficácia da lidocaína |
CN109796521B (zh) * | 2017-11-17 | 2022-04-19 | 上海医药工业研究院 | 一种罗米地辛醋酸盐晶型及其制备方法 |
CN111187337B (zh) * | 2018-11-15 | 2023-01-24 | 上海医药工业研究院 | 罗米地辛一异丙醇溶剂合物及其晶型、制备方法和应用 |
US20220049213A1 (en) * | 2018-12-24 | 2022-02-17 | Marrone Bio Innovations, Inc. | A method for increasing romidepsin production from fermentation broth |
CN113813366A (zh) * | 2020-06-18 | 2021-12-21 | 中国科学院深圳先进技术研究院 | 罗米地辛在制备预防和治疗抗新冠肺炎新型冠状病毒的药物中的应用 |
WO2021253338A1 (zh) * | 2020-06-18 | 2021-12-23 | 中国科学院深圳先进技术研究院 | 罗米地辛在预防和治疗冠状病毒相关疾病中的应用 |
Family Cites Families (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8817743D0 (en) | 1988-07-26 | 1988-09-01 | Fujisawa Pharmaceutical Co | Fr901228 substance & preparation thereof |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5545522A (en) | 1989-09-22 | 1996-08-13 | Van Gelder; Russell N. | Process for amplifying a target polynucleotide sequence using a single primer-promoter complex |
JPH0764872A (ja) | 1993-08-26 | 1995-03-10 | Fujitsu Ten Ltd | データ記憶制御装置 |
US5578832A (en) | 1994-09-02 | 1996-11-26 | Affymetrix, Inc. | Method and apparatus for imaging a sample on a device |
US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
US5776905A (en) | 1996-08-08 | 1998-07-07 | The Board Of Trustees Of The Leland Stamford Junior University | Apoptotic regression of intimal vascular lesions |
US6030961A (en) | 1997-03-11 | 2000-02-29 | Bar-Ilan Research & Development Co., Ltd. | Oxyalkylene phosphate compounds and uses thereof |
US6124495A (en) | 1997-03-11 | 2000-09-26 | Beacon Laboratories, Inc. | Unsaturated oxyalkylene esters and uses thereof |
JP3494624B2 (ja) | 1997-09-02 | 2004-02-09 | 住友製薬株式会社 | 新規な環状テトラペプチド誘導体とその医薬用途 |
JPH11335375A (ja) | 1998-05-20 | 1999-12-07 | Mitsui Chem Inc | ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体 |
US6214986B1 (en) | 1998-10-07 | 2001-04-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of bcl-x expression |
US20070148228A1 (en) | 1999-02-22 | 2007-06-28 | Merrion Research I Limited | Solid oral dosage form containing an enhancer |
US6723338B1 (en) | 1999-04-01 | 2004-04-20 | Inex Pharmaceuticals Corporation | Compositions and methods for treating lymphoma |
EA007649B1 (ru) | 1999-09-08 | 2006-12-29 | Слоан-Кеттеринг Инститьют Фор Кэнсер Рисёч | Ингибиторы гистондеацетилазы, вызывающие дифференцировку клеток, и их применение |
US6828302B1 (en) | 1999-12-08 | 2004-12-07 | Xcyte Therapies, Inc. | Therapeutic uses of depsipeptides and congeners thereof |
CA2393682C (en) | 1999-12-08 | 2012-01-31 | Xcyte Therapies, Inc. | Depsipeptide and congeners thereof for use as immunosuppressants |
CA2317003A1 (en) | 2000-02-28 | 2001-08-28 | Hidenori Nakajima | Gene expression potentiator |
JP2001348340A (ja) | 2000-06-07 | 2001-12-18 | Yamanouchi Pharmaceut Co Ltd | ヒストン脱アセチル化酵素阻害剤 |
JP4810784B2 (ja) | 2000-07-17 | 2011-11-09 | アステラス製薬株式会社 | 還元型fk228およびその用途 |
AU2001285042A1 (en) * | 2000-08-18 | 2002-03-04 | The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor |
WO2002020817A1 (en) * | 2000-09-01 | 2002-03-14 | Fujisawa Pharmaceutical Co., Ltd. | A method of producing fr901228 |
AU2002243231A1 (en) | 2000-11-21 | 2002-07-24 | Wake Forest University | Method of treating autoimmune diseases |
JP2005507231A (ja) | 2001-01-10 | 2005-03-17 | アメリカ合衆国 | 甲状腺新生物の診断および治療におけるヒストン脱アセチル酵素阻害剤 |
ES2236481T3 (es) * | 2001-01-16 | 2005-07-16 | Glaxo Group Limited | Combinacion farmaceutica que contiene una 4-quinazolinamina y paclitaxel, carboplatino o vinorelbina para el tratamiento de cancer. |
US7219016B2 (en) | 2001-04-20 | 2007-05-15 | Yale University | Systems and methods for automated analysis of cells and tissues |
US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
WO2002090534A1 (en) | 2001-05-02 | 2002-11-14 | The Regents Of The University Of California | Method for treating neurodegenerative, psychiatric and other disorders with deacetylase inhibitors |
NZ529792A (en) | 2001-05-30 | 2007-04-27 | Univ Michigan | Small molecule antagonists of Bcl-2 family proteins |
US7171311B2 (en) | 2001-06-18 | 2007-01-30 | Rosetta Inpharmatics Llc | Methods of assigning treatment to breast cancer patients |
PL210794B1 (pl) | 2001-08-21 | 2012-03-30 | Astellas Pharma Inc | Zastosowanie inhibitora deacetylazy histonowej FK228 lub jego soli |
US20040259772A1 (en) | 2001-08-24 | 2004-12-23 | Antonio Fojo | Use of a histone deacetylase inhibitor to increase the entry of an adenoviral agent into a cell |
EP1293205A1 (en) | 2001-09-18 | 2003-03-19 | G2M Cancer Drugs AG | Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease |
US6706686B2 (en) | 2001-09-27 | 2004-03-16 | The Regents Of The University Of Colorado | Inhibition of histone deacetylase as a treatment for cardiac hypertrophy |
WO2003035843A2 (en) | 2001-10-25 | 2003-05-01 | Buck Institute For Age Research | Screening system for modulators of her2 mediated transcription and her2 modulators identifed thereby |
US7354928B2 (en) | 2001-11-01 | 2008-04-08 | The Regents Of The University Of Michigan | Small molecule inhibitors targeted at Bcl-2 |
WO2003053468A1 (en) | 2001-12-21 | 2003-07-03 | Universite Libre De Bruxelles | Method for obtaining the elimination of integrated and functional viruses from infected mammal cells |
US20030134423A1 (en) | 2002-01-04 | 2003-07-17 | Chu Yong Liang | Compounds for delivering substances into cells |
AU2003219803B8 (en) | 2002-02-15 | 2005-08-25 | Sloan-Kettering Institute For Cancer Research | Method of treating TRX mediated diseases |
US7488712B2 (en) | 2002-02-20 | 2009-02-10 | Kyushu Institute Of Technology | Histone deacetylase inhibitors and methods for producing the same |
EP1487426B1 (en) | 2002-03-04 | 2012-08-22 | Sloan-kettering Institute For Cancer Research | Methods of inducing terminal differentiation |
AU2003226014A1 (en) | 2002-03-28 | 2003-10-13 | Brigham And Women's Hospital, Inc. | Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease |
MXPA04009761A (es) | 2002-04-05 | 2005-05-27 | Fujisawa Pharmaceutical Co | Dipsipeptido para terapia de cancer renal. |
CN100566711C (zh) | 2002-04-15 | 2009-12-09 | 斯隆-凯特林癌症研究院 | 治疗癌症的化合物及其用途 |
US6809118B2 (en) | 2002-07-25 | 2004-10-26 | Yih-Lin Chung | Methods for therapy of radiation cutaneous syndrome |
US20040002447A1 (en) | 2002-06-04 | 2004-01-01 | Regents Of The University Of California | Induction of insulin expression |
US20050065596A1 (en) | 2002-07-24 | 2005-03-24 | Xufan Tseng | Stents capable of controllably releasing histone deacetylase inhibitors |
CA2495354A1 (en) | 2002-08-20 | 2004-03-04 | Yamanouchi Pharmaceutical Co., Ltd. | An agent for inhibiting articular cartilage extracellular matrix degradation |
JP2006501267A (ja) | 2002-09-13 | 2006-01-12 | バージニア コモンウェルス ユニバーシティー | 白血病の処置のためのa)N−{5−[4−(4−メチル−ピペラジノ−メチル)−ベンゾイルアミド]−2−メチルフェニル}−4−(3−ピリジル)−2−ピリミジン−アミンおよびb)ヒストンデアセチラーゼインヒビターの組合せ剤 |
SE0300098D0 (sv) | 2003-01-15 | 2003-01-15 | Forskarpatent I Syd Ab | Use of cyclin D1 inhibitors |
US20050222013A1 (en) | 2003-01-16 | 2005-10-06 | Georgetown University | Methods for the use of inhibitors of histone deacetylase as synergistic agents in cancer therapy |
JPWO2004074478A1 (ja) | 2003-02-19 | 2006-06-01 | アステラス製薬株式会社 | ヒストンデアセチラーゼ阻害剤の抗腫瘍効果の予測方法 |
JP4588634B2 (ja) | 2003-04-25 | 2010-12-01 | 尚巳 岡田 | 遺伝子導入効率増強剤および商業的パッケージ |
US20040213826A1 (en) | 2003-04-28 | 2004-10-28 | Marx Steven O. | Medical devices and methods for inhibiting proliferation of smooth muscle cells |
EP1491188A1 (en) | 2003-06-25 | 2004-12-29 | G2M Cancer Drugs AG | Topical use of valproic acid for the prevention or treatment of skin disorders |
EP2238982B8 (en) | 2003-06-27 | 2013-01-16 | Astellas Pharma Inc. | Therapeutic agent for soft tissue sarcoma |
DE602004010407T2 (de) | 2003-07-23 | 2008-10-16 | Bayer Pharmaceuticals Corp., West Haven | Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden |
DK1663194T3 (da) | 2003-08-26 | 2010-07-19 | Merck Hdac Res Llc | Anvendelse af SAHA til behandling af mesotheliom |
CN1964714B (zh) | 2003-08-29 | 2011-09-28 | Hdac默克研究有限责任公司 | 辛二酰苯胺异羟肟酸和吉西他滨在制备用于治疗癌症的药物中的用途 |
US20050059682A1 (en) | 2003-09-12 | 2005-03-17 | Supergen, Inc., A Delaware Corporation | Compositions and methods for treatment of cancer |
CN1878556A (zh) | 2003-09-18 | 2006-12-13 | 康宾纳特克斯公司 | 治疗肿瘤的联合药物 |
ES2425083T3 (es) | 2003-09-25 | 2013-10-11 | Astellas Pharma Inc. | Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II |
US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
US20070110719A1 (en) | 2003-11-14 | 2007-05-17 | Holm Per S | Novel use of adenoviruses and nucleic acids that code for said viruses |
JP2007511212A (ja) | 2003-11-14 | 2007-05-10 | ホルム,ペル・ゾンネ | 新規アデノウイルス、それをコードする核酸及びその使用 |
WO2005053609A2 (en) | 2003-11-26 | 2005-06-16 | Guilford Pharmaceuticals Inc. | Methods of nad+-dependent deacetylase inhibitors |
EP1713460A2 (en) | 2003-12-10 | 2006-10-25 | Wisconsin Alumni Research Foundation | Fk228 analogs and their use as hdac-inhibitors |
US7951780B2 (en) | 2004-02-25 | 2011-05-31 | Astellas Pharma Inc. | Antitumor agent |
US20050187148A1 (en) | 2004-02-25 | 2005-08-25 | Yoshinori Naoe | Antitumor agent |
CA2557568C (en) | 2004-02-27 | 2014-05-27 | Jane Trepel | Pharmacodynamic assays using flow cytometry |
GB0405349D0 (en) | 2004-03-10 | 2004-04-21 | Univ Birmingham | Cancer therapy and medicaments therefor |
ITMI20040876A1 (it) | 2004-04-30 | 2004-07-30 | Univ Degli Studi Milano | Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari |
PT1591109E (pt) | 2004-04-30 | 2008-09-05 | Desitin Arzneimittel Gmbh | Formulação exibindo libertação bifásica compreendendo um inibidor da desacetilase de histona |
US20050261174A1 (en) | 2004-05-20 | 2005-11-24 | Paul Lewer | Insecticidal activity of a cyclic peptide |
WO2005117930A2 (en) | 2004-06-04 | 2005-12-15 | Sloan-Kettering Institute For Cancer Research | Use of thioredoxin measurements for diagnostics and treatments |
WO2005123089A2 (en) | 2004-06-10 | 2005-12-29 | Kalypsys, Inc. | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease |
US20060018921A1 (en) | 2004-07-16 | 2006-01-26 | Baylor College Of Medicine | Histone deacetylase inhibitors and cognitive applications |
AU2005281704A1 (en) | 2004-09-06 | 2006-03-16 | Nycomed Gmbh | Novel pyrazolopyrimidines |
WO2006055621A2 (en) | 2004-11-17 | 2006-05-26 | The University Of Chicago | Histone deacetylase inhibitors and methods of use |
WO2006060382A2 (en) | 2004-11-30 | 2006-06-08 | Trustees Of The University Of Pennsylvania | Use of hdac and/or dnmt inhibitors for treatment of ischemic injury |
WO2006060429A2 (en) | 2004-12-03 | 2006-06-08 | Novartis Ag | Identification of variants in histone deacetylase 1 (hdac1) to predict drug response |
US20060128660A1 (en) | 2004-12-10 | 2006-06-15 | Wisconsin Alumni Research Foundation | FK228 analogs and methods of making and using the same |
GB0511266D0 (en) | 2005-06-02 | 2005-07-13 | Trust | Chemical compounds |
EP1743654A1 (en) | 2005-07-15 | 2007-01-17 | TopoTarget Germany AG | Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases |
WO2007040522A1 (en) | 2005-09-30 | 2007-04-12 | The Ohio State Research Foundation | Antitumor agents |
TW200800354A (en) * | 2005-10-28 | 2008-01-01 | Kyowa Hakko Kogyo Kk | Concentration crystallizer and method |
AU2006315760A1 (en) | 2005-11-10 | 2007-05-24 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Materials and methods for ABCB1 polymorphic variant screening, diagnosis, and treatment |
EP1965824A4 (en) | 2005-11-18 | 2011-10-19 | Gloucester Pharmaceuticals Inc | METABOLITENE DERIVATIVES OF HDAC INHIBITOR FK228 |
US20100137239A1 (en) | 2006-04-24 | 2010-06-03 | Gloucester Pharmaceuticals | Gemcitabine combination therapy |
WO2007146730A2 (en) | 2006-06-08 | 2007-12-21 | Gloucester Pharmaceuticals | Deacetylase inhibitor therapy |
JP2009539862A (ja) | 2006-06-09 | 2009-11-19 | メリオン リサーチ Iii リミテッド | 強化剤を含む固体経口投与剤形 |
US7857804B2 (en) | 2006-09-01 | 2010-12-28 | Mccaffrey Timothy A | Use of Bcl inhibitors for the prevention of fibroproliferative reclosure of dilated blood vessels and other iatrogenic fibroproliferative disorders |
CN101801994A (zh) | 2006-12-29 | 2010-08-11 | 格洛斯特制药公司 | 制备Romidepsin |
BRPI0720734A2 (pt) | 2006-12-29 | 2014-01-07 | Gloucester Pharmaceuticals Inc | Preparação da romidepsina |
CN102276689A (zh) | 2011-05-09 | 2011-12-14 | 中国药科大学 | 组蛋白去乙酰化酶抑制剂fk228的化学合成方法及其应用 |
-
2011
- 2011-07-12 US US13/181,460 patent/US20120190817A2/en not_active Abandoned
- 2011-07-12 SG SG2013002266A patent/SG187032A1/en unknown
- 2011-07-12 NZ NZ706052A patent/NZ706052A/en not_active IP Right Cessation
- 2011-07-12 WO PCT/US2011/043680 patent/WO2012009336A1/en active Application Filing
- 2011-07-12 KR KR1020137003355A patent/KR20130092557A/ko not_active Application Discontinuation
- 2011-07-12 BR BR112013000673A patent/BR112013000673A2/pt not_active IP Right Cessation
- 2011-07-12 RU RU2013105700A patent/RU2607634C2/ru not_active IP Right Cessation
- 2011-07-12 NZ NZ605526A patent/NZ605526A/en not_active IP Right Cessation
- 2011-07-12 CN CN2011800437821A patent/CN103108648A/zh active Pending
- 2011-07-12 AU AU2011279303A patent/AU2011279303B2/en not_active Ceased
- 2011-07-12 RU RU2016149485A patent/RU2016149485A/ru not_active Application Discontinuation
- 2011-07-12 SG SG10201505475XA patent/SG10201505475XA/en unknown
- 2011-07-12 EP EP11739216.7A patent/EP2593123B1/en active Active
- 2011-07-12 MX MX2013000446A patent/MX342913B/es active IP Right Grant
- 2011-07-12 JP JP2013519762A patent/JP6049614B2/ja active Active
- 2011-07-12 ES ES11739216T patent/ES2755909T3/es active Active
- 2011-07-12 UA UAA201301639A patent/UA114074C2/uk unknown
- 2011-07-12 CA CA2804795A patent/CA2804795A1/en not_active Abandoned
- 2011-07-12 MY MYPI2013700065A patent/MY185130A/en unknown
-
2014
- 2014-05-19 US US14/281,654 patent/US8980825B2/en active Active
- 2014-07-22 US US14/338,278 patent/US20140336132A1/en not_active Abandoned
-
2015
- 2015-02-05 US US14/615,384 patent/US9518094B2/en active Active
- 2015-11-10 US US14/937,804 patent/US9624271B2/en active Active
-
2016
- 2016-07-28 JP JP2016147920A patent/JP6490632B2/ja active Active
-
2018
- 2018-12-04 JP JP2018227150A patent/JP2019052177A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2016149485A (ru) | Твердые формы ромидепсина и их применение | |
ES2721059T3 (es) | Formulaciones que contienen dapagliflozina amorfa | |
JP2013505011A5 (ru) | ||
CO6241094A2 (es) | Peliculas que comprenden una pluralidad de polimeros | |
JP2017519098A5 (ru) | ||
JP2010539237A5 (ru) | ||
NZ610104A (en) | Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio) acetic acid and uses thereof | |
NZ596883A (en) | Solid pharmaceutical compositions and processes for their production | |
JP2016512425A5 (ru) | ||
DE69906269T2 (de) | Wässriges verfahren zur herstellung fester paroxetin-dispersionen | |
JP2010166921A5 (ru) | ||
CN104448841B (zh) | 一种聚乳酸乙醇酸与聚丙烯酸改进聚肽膜亲水性与柔顺性的方法 | |
CO6721004A2 (es) | Polímero fabricado a partir de ácido maleico, éter de alilo y acetato de vinilo y la preparación y uso de dicho polímero | |
Wang et al. | Supramolecular Hydrogels of Indole‐Capped Short Peptides as Vaccine Adjuvants | |
RU2007129264A (ru) | Полиморф cci-779 и его применение | |
FR2935143B1 (fr) | Nouveaus derives (poly)aminoalkylaminoalkylamides, alkyl-urees, ou alkyl-sulfonamides d'epipodophyllotoxine, leur procede de preparation et leur application en therapeuthique comme agent cancereux | |
RU2007103195A (ru) | Пероральная композиция тедисамила с замедленным высвобождением, обладающая свойством задержки в желудке | |
RU2011148101A (ru) | Новые кристаллы сольватов | |
JP2008230866A (ja) | 空隙形成剤及び多孔質成形体 | |
AR082139A1 (es) | Preparacion recubiertas con particulas finas | |
WO2012027218A3 (en) | Peptide-modified surfaces for cell culture | |
CN105754354A (zh) | 一种用聚对二氧环己酮与聚己内酯-聚乙二醇改进聚乙烯醇膜耐水性及柔顺性的方法 | |
US10590103B2 (en) | Crystalline 4-amino-2-(2,6-dioxopiperidine-3-YL)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof | |
JP2005139457A5 (ru) | ||
JP2013536823A5 (ru) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20191217 |